Amylyx Pharmaceuticals Inc
AMLX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.48B
Close$
$2.33
87.2% downside
Current Fair Value
87.2% downsideOvervalued by 87.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.48 Billion |
|---|---|
| Enterprise Value | $1.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.53 |
| Beta | -0.2 |
| Outstanding Shares | 110,563,360 |
Return
| Return on Equity | -54.95% |
|---|---|
| Return on Assets | -51.13% |
| Return on Invested Capital | -54.86% |
Valuation & Multiples
| P/E Ratio | -12.01 |
|---|---|
| PEG | -80.18 |
| Price to Sales | - |
| Price to Book Ratio | 9.1 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.23 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 20.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 120.69% |
|---|---|
| Total Invested | $403,327▼ 99.97% |
| Investors Holding | 5▼ 176.00% |
ESG Score
No data